Any deal would be similar to what you see in overseas deals where the overseas company takes care of distribution of current and future indications for that drug. Quite a few of those deals are signed pre-approval and are contingent upon approval. The one question is if any big pharma is going to offer an appropriate deal. Ten to one they're all low-balling it.